Xellia Pharmaceuticals operates internationally, with offices and production sites found across the globe. Xellia's Corporate Headquarters are located in Copenhagen Denmark, where not only a great deal of administrative tasks take place, but also is a key production hub.
Click on the various locations on the map to learn more about each site.
Copenhagen (Corporate HQ)
Xellia Copenhagen houses Xellia’s corporate headquarters and is also a main production site; manufacturing, stability testing and packaging both sterile APIs and FDFs. With more than 600 employees, the corporate functions of Quality & Regulatory Affairs, Supply Chain, HR, Legal, Finance, Sales & Marketing, Branding & Communications, Global Technical Support, and Environment, Health & Safety are headed in Copenhagen. Additional to the grand production facility, the site also offers job opportunities within technical operations and manufacturing. Educational backgrounds of the employees at the site vary from PhD, MSc, Engineers, scientists and laboratory technicians to operators.
Raleigh (US HQ)
Xellia Raleigh houses the U.S. headquarters and is also one of Xellia’s manufacturing sites. We have competencies in lyophilized and liquid sterile manufacturing with more than 120 engaged and dedicated colleagues focused on delivering the highest quality products to our customers and patients. The departments currently on site include; Production, Quality, HR, Planning, Finance and Global Technical Support.
Bangalore
Xellia Bangalore is integrated with Xellia’s global functions to support manufacturing operations for Xellia Products at Contract Manufacturing Organizations (CMOs) in India and to ensure Quality Assurance at External Suppliers of Xellia in the geographical region. Xellia Bangalore has 25 employees, working within Sales & Marketing, External Supplier Quality Assurance, Regulatory Affairs, Global Product Supply, Finance and IT. Xellia's business presence in India offers a platform for commercialization of Xellia's portfolio of high-quality anti-infective products for the benefit of the patient population in India.
Budapest
Xellia Budapest is one of the company's API manufacturing sites producing five different life-saving anti-infectives by fermentation technology. More than 250 employees are working in the fields of biotechnology, chemistry, Quality Affairs, Engineering, Logistics, Finance, EHS, IT and HR, ensuring business continuity and development. Typical educational backgrounds of employees at the site are MSc and Engineers in biotechnology, chemistry, special professional disciplines and chemical technician graduates.
Cleveland
Our new Cleveland production site will operate alongside Xellia’s existing production facility in Raleigh, producing sterile injectable products. The site includes four manufacturing units for sterile injectables, targeted to commence commercial production by 2018. Xellia Cleveland has currently more than 130 employees and is planning to bring around 70 new jobs to the site with the potential for more in the future across a range of departments, including; manufacturing, supply chain, distribution, quality, engineering, human resources and finance.
Oslo
Xellia Oslo is the company's API R&D center of excellence. In state-of-the-art labs (inaugurated late 2014), more than 40 people are working in the fields of biotechnology (strain development, fermentation development and purification development), synthetic organic chemistry development and analytical development. Typical educational backgrounds are PhD, MSc and Engineers in biotechnology or chemistry, covering our professional career ladders of Principal Scientist, Senior Scientist, Scientist, Senior Engineer and Engineer.
Shanghai
Xellia Shanghai Rep Office is a multi-functional group providing support to Xellia's operations in the Asia Pacific region. We have currently five employees working within Regulatory Affairs, Sales & Marketing, and IT Support functions under a matrix management system. With strong economic growth in the Asia Pacific region, we expect to expand Xellia's activities in the region, serving more customers and patients.
Taizhou
Xellia Taizhou is one of the designated sites for API manufacturing. Three APIs are produced here: Vancomycin, Bacitracin, and Bacitracin Zinc. More than 210 people are working at Xellia Taizhou, including fermentation specialists, chemists, engineers, analysts, quality specialists, and operators. 70 percent of our employees have college or equivalent degrees, and most technical employees have an educational background in pharmaceutical related disciplines. The positions at our site include operator, shift leader, supervisor, engineer, specialist, and manager.
Tokyo
Nippon Axellia Sales Office is located in the center of Tokyo. We have four employees, two working within Sales, one employee representing Regulatory Affairs and one employee working within Accounting and General Affairs. We sell not only Xellia's APIs and FDFs, but also third party products such as human or animal health APIs for the generic market in Japan.
Zagreb
Xellia Zagreb is the company's FDF R&D center of excellence, specialized in pharmaceutical technology (formulation development and manufacturing process development), analytical development and in vitro biology, primarily microbiology. The site was established in 2009 and has been continuously expanding since. In addition to R&D, which also incorporates Project Management and Clinical R&D, other functions represented at the site include IP, Regulatory Affairs, Quality, Global Product Supply and Sales & Marketing. The multifunctional team of 100 employees consists of scientists with PhD, MSc and BSc degrees in pharmacy, biotechnology, chemistry, and biology, and highly skilled technicians/administrative staff.
